Askina Calgitrol Paste Diabetic Foot Ulcers

Overview

The purpose of this study is to assess the efficacy of Askina® Calgitrol® Paste in reducing local infection in subjects treated for mildly infected Diabetic Foot Ulcers (DFU) with Askina® Calgitrol® Paste.

Full Title of Study: “A NON-CONTROLLED PROSPECTIVE COHORT STUDY OF THE USE OF ASKINA® CALGITROL® PASTE + STANDARD OF CARE ON MILDLY INFECTED, NON-ISCHAEMIC DIABETIC FOOT ULCERS”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2014

Interventions

  • Device: Askina Calgitrol paste

Arms, Groups and Cohorts

  • Experimental: Askina Calgitrol Paste

Clinical Trial Outcome Measures

Primary Measures

  • Clinical signs of local infection (Presence of erythema, pain, tenderness, warmth or induration)
    • Time Frame: At day 0, day 2 and weekly in a period of a maximum of 6 weeks
    • During each of the day 2 and weekly control visits, the investigator will observe the wound visually and assess it for signs of Clinical infection, using the Guidelines for Diabetic Foot Ulcer infection of the Infectious Diseases Society of America. The investigator will score the degree of infection of the wound according to a table adapted from the 8 items wound score for diabetic foot infections. In general, treatment with Askina Calgitrol Paste will be discontinued when local infection has resolved or when it was worsened since the last control visit. However, treatment of Askina Calgitrol Paste will continued after 4 weeks of treatment only if there are signs of improvement. The treatment period of Askina Calgitrol Paste will last a maximum of 6 weeks.

Secondary Measures

  • Adverse events or Adverse device related event
    • Time Frame: At day 2 and weekly in a period of a maximum of 6 weeks
  • Evaluation of wound bed (necrosis, slough, granulation, epithelialisation)
    • Time Frame: At day 0, day 2 and weekly in a period of a maximum of 6 weeks
    • It will be assessed visually by the investigator.
  • Ease of use of Askina Calgitrol Paste
    • Time Frame: Daily or at every change of dressing, in a period of a maximum of 6 weeks
    • Ease of application and removal of dressing will be assessed by the subject/subject’s relatives and the investigator using a rating scale of 1 (very easy) to 5 (very difficult). Dressing change at home will be evaluated in a patient diary by the patient or the carer and dressing changes in the clinic by the investigator.
  • Wound surface area
    • Time Frame: At day 0, day 2 and weekly in a period of a maximum of 6 weeks
    • It will be measured by Visitrak Wound Measurement System at each clinic visit by the healthcare professional.

Participating in This Clinical Trial

Inclusion Criteria

  • Subject older than 18 years old – Provision of written consent by the subject themselves – Subjects with a Texas stage I-B wound below the malleolus: superficial and infected (Wagner-Armstrong classification system). – Subjects with a mildly infected wound according to the Infectious Diseases Society of America (IDSA). – Size of wound >2 cm2. – Absence of ischaemia of the lower limb as assessed by : 1. Transcutaneous oxygen pressure (TcPO2) > 30 mmHg. 2. Toe pressure > 50 mmHg. 3. Ankle pressure > 70 mmHg. – Capable of following Study instructions. – Compliant with treatment and in particular with off-loading regime. – Stable management of their diabetes as defined by an HbA1C (%) of 12% Exclusion Criteria:

  • Subjects who are <18 years old. – Subjects with a documented sensitivity to alginates or silver. – Subjects taking a medication or using a device comprising silver. – Subjects already taking antibiotics before enrolment – Subjects undergoing dialysis. – Subjects using therapy known to be immune-compromising such as systemic anti-neoplastic drugs and/or systemic cortico-steriods. – Pregnancy – Breast-feeding – Currently participating in another clinical trial, or who have participated in another clinical trial in the last 6 weeks or who have previously taken part in this study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • BBraun Medical SAS
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.